Combined Antibody Screening for Celiac and Diabetes Evaluation

Part of paid clinical trials in Seattle, Washington.

Sponsor
Pacific Northwest Research Institute
Study ID
NCT04677699
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
ALL
Age
1 Day - 7 Years
Healthy Volunteers
Accepted

Interventions

  • Combined Risk Score — DIAGNOSTIC_TEST
    Several factors will be analyzed to assign each subject combined risk score. This will assess the subject's risk of developing Type 1 Diabetes and/or Celiac Disease.

Study Details

The CASCADE Study (Combined Antibody Screening for Celiac and Diabetes Evaluation) is an observational study whose primary goal is to show that population-based screening for advanced prediction of type 1 diabetes (T1D) and celiac disease (CD) is feasible to prevent diabetic ketoacidosis (DKA), improve celiac disease diagnosis, and ultimately gain public health acceptance to facilitate future prevention. It has two arms, a Birth Cohort and a Kids (cross sectional) Cohort.

Key Dates

Start date
Dec 31, 2020
Status verified
Dec 2020
Primary completion
Dec 31, 2022
Completion
Jun 30, 2026

Study Design

Enrollment
64,410 participants (estimated)

Arms

  • Arm: Birth Cohort
    Newborns less than 8 months old and born in the state of Washington.
  • Arm: Kids Cohort
    Children ages 4-7 years and born in the state of Washington.

Primary Outcome Measure

Diagnosis of Type 1 Diabetes [ Time Frame: 5 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
Pacific Northwest Research InstituteSeattleWashington98122-

Find similar trials in Seattle, WA

By condition
Celiac diseaseType 1 diabetes
By specialty
GastroenterologyAutoimmune diseaseEndocrinology
By research site
Pacific Northwest Research Institute· Seattle, WA

Related Studies